Dermatomyositis Pipeline Summary

DelveInsight’s, “Dermatomyositis - Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Dermatomyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dermatomyositis: Understanding

Dermatomyositis: Overview

Dermatomyositis (DM) is a rare, chronic idiopathic inflammatory myopathy characterized by proximal skeletal muscle weakness accompanied by distinctive cutaneous manifestations. The disease affects both adults and children and is associated with autoimmune dysregulation, genetic susceptibility, and environmental triggers, with adults having an increased risk of malignancy, particularly within the first few years after diagnosis. Hallmark skin findings include heliotrope rash, Gottron papules, Gottron sign, shawl sign, V sign, periungual telangiectasia, and photosensitivity.

Patients commonly present with symmetrical proximal muscle weakness, fatigue, dysphagia, myalgia, and reduced physical function, while interstitial lung disease, cardiac involvement, and gastrointestinal complications may occur in severe cases. Dermatomyositis significantly impairs quality of life and is associated with increased morbidity and mortality if not promptly diagnosed and treated.

The pathophysiology of dermatomyositis involves complement-mediated microangiopathy and immune-mediated muscle and skin injury. Activation of the innate and adaptive immune systems, particularly the type I interferon pathway, leads to endothelial damage, perifascicular ischemia, inflammatory cell infiltration, and muscle fiber atrophy. Autoantibodies such as anti-Mi-2, anti-MDA5, anti-TIF1-?, anti-NXP2, anti-SAE, and anti-Jo-1 define distinct clinical phenotypes and are associated with varying risks of malignancy, interstitial lung disease, and disease severity.

Diagnosis is based on characteristic clinical features supported by elevated creatine kinase (CK) and other muscle enzymes, myositis-specific autoantibody testing, electromyography, magnetic resonance imaging (MRI) of affected muscles, skin or muscle biopsy, and pulmonary evaluation to assess interstitial lung disease. Malignancy screening is recommended in adult-onset disease because of the well-established association between dermatomyositis and cancer.

Management of dermatomyositis aims to suppress inflammation, restore muscle strength, prevent organ damage, and improve long-term functional outcomes. Systemic corticosteroids remain the cornerstone of initial therapy and are commonly combined with steroid-sparing immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, or cyclophosphamide, particularly in patients with severe muscle or lung involvement. Intravenous immunoglobulin (IVIG) has demonstrated efficacy in refractory disease, and biologic therapies including rituximab are used in selected patients, while targeted therapies such as Janus kinase (JAK) inhibitors and other immune-modulating agents are under active clinical investigation. Comprehensive care also includes physical rehabilitation, photoprotection, management of dysphagia and interstitial lung disease, routine malignancy surveillance, and regular monitoring of disease activity and treatment-related adverse effects.

"Dermatomyositis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dermatomyositis pipeline landscape is provided which includes the disease overview and Dermatomyositis treatment guidelines. The assessment part of the report embraces, in depth Dermatomyositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dermatomyositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dermatomyositis R&D. The therapies under development are focused on novel approaches to treat/improve Dermatomyositis.

Dermatomyositis Emerging Drugs Chapters

This segment of the Dermatomyositis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dermatomyositis Emerging Drugs

Dazukibart: Pfizer

Dazukibart (PF-06823859) is an investigational humanized monoclonal antibody developed by Pfizer for the treatment of idiopathic inflammatory myopathies, including dermatomyositis (DM) and polymyositis (PM). The antibody selectively neutralizes interferon-beta (IFN-?), a key cytokine in the type I interferon pathway that drives immune-mediated muscle inflammation and cutaneous manifestations associated with these disorders. Dazukibart is currently being evaluated in Phase III clinical development, including a multicenter, open-label extension study assessing its long-term safety, tolerability, and efficacy in adults with DM or PM who previously participated in qualifying dazukibart trials. The extension study administers intravenous dazukibart every four weeks for up to 48 weeks, followed by a safety follow-up period.

PN-101: Paean Biotechnology Inc.

PN-101 is an investigational biologic therapy developed by Paean Biotechnology for the treatment of refractory dermatomyositis and polymyositis. It consists of allogeneic mitochondria isolated from umbilical cord-derived mesenchymal stem cells and is designed to restore mitochondrial function, improve muscle regeneration, and reduce inflammation in affected muscle tissue. PN-101 is currently being evaluated in a randomized, double-blind, placebo-controlled Phase II trial assessing the efficacy and safety of a single intravenous dose in patients with refractory disease, with efficacy primarily measured using the International Myositis Assessment and Clinical Studies Group Total Improvement Score (IMACS-TIS).

Further product details are provided in the report……..

Dermatomyositis: Therapeutic Assessment

This segment of the report provides insights about the different Dermatomyositis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Dermatomyositis
• There are approx. 12+ key companies which are developing the therapies for Dermatomyositis. The companies which have their Dermatomyositis drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Dermatomyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dermatomyositis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Dermatomyositis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dermatomyositis drugs.

Dermatomyositis Report Insights

• Dermatomyositis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dermatomyositis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dermatomyositis drugs?
• How many Dermatomyositis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dermatomyositis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dermatomyositis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dermatomyositis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• Paean Biotechnology Inc.
• Restem, LLC.
• NovelMed Therapeutics
• Lakefront Biotherapeutics
• Luminary Therapeutics
• Cabaletta Bio

Key Products

• Dazukibart
• PN-101
• Restem-L
• NM8074
• GLPG3667
• LMY-922
• CABA-201